Millipore Sigma Vibrant Logo

500609 Temozolomide - CAS 85622-93-1 - Calbiochem

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
85622-93-1C₆H₆N₆O₂

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
5.00609.0001
Récupération des données relatives à la disponibilité...
Disponibilité limitée
Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      Flacon en verre 50 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      Demander le prix
      Description
      OverviewA cell-permeable, orally bioavailable, blood-brain barrier-permeant MTIC [5-(3-methyltriazen-1-yl-)-imidazole-4-carboxamide] prodrug whose in vivo DNA alkylating activity is employed in anticancer therapy. MGMT (O6-methylguanine DNA methyl transferase) repairs TMZ-damaged DNA lesion by covalently transferring O6-methylation on guanine residues to a cysteine residue on the MGMT, forming the basis of TMZ-resistance in cancer treatment.

      Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
      Catalogue Number500609
      Brand Family Calbiochem®
      SynonymsNSC 362856, 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, CCRG 81045, TMZ, 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
      References
      ReferencesNeyns, B., et al. 2010. Cancer 116, 2868.
      Marchesi, F., et al. 2007. Pharmacol. Res. 56, 275.
      Chakravarti, A., et al. 2006. Clin. Cancer Res. 12, 4738.
      Natsume, A., et al. 2005. Cancer Res. 65, 7573.
      Jen, J.F., et al. 2000. Pharm. Res. 17, 1284.
      Product Information
      CAS number85622-93-1
      FormOff-white solid
      Hill FormulaC₆H₆N₆O₂
      Chemical formulaC₆H₆N₆O₂
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetDNA guanine residues
      Purity≥99% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 23/24/25-36/37/38-45-46

      Toxic by inhalation, in contact with skin and if swallowed.
      Irritating to eyes, respiratory system and skin.
      May cause cancer.
      May cause heritable genetic damage.
      S PhraseS: 26-36-45

      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Wear suitable protective clothing.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Harmful & Carcinogenic / Teratogenic
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      5.00609.0001 04055977244991

      Documentation

      Temozolomide - CAS 85622-93-1 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Références bibliographiques

      Aperçu de la référence bibliographique
      Neyns, B., et al. 2010. Cancer 116, 2868.
      Marchesi, F., et al. 2007. Pharmacol. Res. 56, 275.
      Chakravarti, A., et al. 2006. Clin. Cancer Res. 12, 4738.
      Natsume, A., et al. 2005. Cancer Res. 65, 7573.
      Jen, J.F., et al. 2000. Pharm. Res. 17, 1284.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision10-May-2013 JSW
      SynonymsNSC 362856, 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, CCRG 81045, TMZ, 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
      DescriptionA cell-permeable, orally bioavailable, blood-brain barrier-permeant MTIC [5-(3-methyltriazen-1-yl-)-imidazole-4-carboxamide] prodrug whose in vivo DNA alkylating activity is employed in anticancer therapy. MGMT (O6-methylguanine DNA methyl transferase) repairs TMZ-damaged DNA lesion by covalently transferring O6-methylation on guanine residues to a cysteine residue on the MGMT, forming the basis of TMZ-resistance in cancer treatment.
      FormOff-white solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number85622-93-1
      Chemical formulaC₆H₆N₆O₂
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityDMSO (25 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Harmful & Carcinogenic / Teratogenic
      ReferencesNeyns, B., et al. 2010. Cancer 116, 2868.
      Marchesi, F., et al. 2007. Pharmacol. Res. 56, 275.
      Chakravarti, A., et al. 2006. Clin. Cancer Res. 12, 4738.
      Natsume, A., et al. 2005. Cancer Res. 65, 7573.
      Jen, J.F., et al. 2000. Pharm. Res. 17, 1284.